Histone deacetylase inhibitors and mithramycin a impact a similar neuroprotective pathway at a crossroad between cancer and neurodegeneration
Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Format: | article |
| Published: |
2011
|
| Online Access: | http://hdl.handle.net/10725/6140 http://dx.doi.org/10.3390/ph4081183 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.mdpi.com/1424-8247/4/8/1183/htm |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|